Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1856 - Reduced-Intensity Bevacizumab in Progressive Glioblastoma Multiforme (GBM) is Associated with Similar Overall Survival versus Standard-Dosing.

Date

10 Sep 2017

Session

Poster display session

Presenters

Jack Gleeson

Citation

Annals of Oncology (2017) 28 (suppl_5): v109-v121. 10.1093/annonc/mdx366

Authors

J.P. Gleeson1, N. Keegan1, E. Harrold1, D. Kamel1, N. Karadawi1, E. Mammadov1, D. Kelly2, C. O'Leary3, P. O'Halloran4, K. Egan1, S. Molloy1, S. Mac Nally4, B.T. Hennessy1, O.S. Breathnach1, W. Grogan1, P.G. Morris5

Author affiliations

  • 1 Medical Oncology, Beaumont Hospital, 9 - Dublin/IE
  • 2 Medical Oncology, Mater Misericordiae University Hospital University College Dublin, 7 - Dublin/IE
  • 3 Medical Oncology, University Hospital Waterford, 7 - Dublin/IE
  • 4 Neurosurgery Department, Beaumont Hospital, 9 - Dublin/IE
  • 5 Medical Oncology, Beaumont Hospital & RCSI, 9 - Dublin/IE
More

Resources

Abstract 1856

Background

Bevacizumab (BEV) has demonstrated activity in glioblastoma multiforme (GBM), particularly with regard to symptom control, however overall survival (OS) benefits have not been clearly defined in prospective randomised phase III trials. Most studies have used 10mg/Kg q 2wks as standard although some experts suggest a less intensive dose schedule might offer similar benefits at a lower cost and therefore better value.

Methods

We retrospectively analysed data from the prospective database of the national neuro-oncology centre in Ireland. All patients who received BEV at the time of progression for histologically-proven de novo GBM from 2010 to 2016 were included. At our institution there is variable practice between Neuro-Oncologists in terms of BEV dosing schedule - standard BEV dosing (10mg/kg q 2wks or 15mg/kg q 3wks) vs. reduced-intensity BEV (5mg/kg q 2wks or 7.5mg/kg q 3wks). Using the Kaplan-Meier method, we assessed OS in the entire cohort and by BEV dosing schedule.

Results

In total, 118 patients received BEV for progressive GBM. Median OS was 5.6 months for the entire population (range: 0.5-42 months) and OS was 45%, 18% and 2% at 6-, 12- and 24-months, respectively. Patient characteristics by BEV dosing schedule were similar (Table). Median OS was similar in the reduced intensity BEV group (N = 49) at 5.5 months and the standard-dose group (N = 69) at 5.6 months, p=0.55. Quality of life analyses are ongoing.Table:

349P

Standard Dose BEVReduced Intensity BEV
N = 69N = 49P-Value
GenderN (%)N (%)
Male45 (65%)32 (65%)0.99
Female24 (35%)17 (35%)
AGE
< 45 years10 (14.5%)8 (16%)0.92
45-65 years42 (60.9%)28 (57%)
> 65 years17 (24.6%)13 (27%)
MGMTKnown (50/69)Known (36/49)
Methylated20 (40%)17 (47%)0.50
Unmethylated30 (60%)19 (53%)
Time from Diagnosis to BEV start
< 12 months36 (52%)24 (49%)
12-18 Months16 (23%)12 (24%)0.94
> 18 months17 (25%)13 (27%)
Median Overall Survival post BEV5.6 Months5.5 Months0.55

Conclusions

In this large heterogeneous cohort of patients, OS was similar in patients who received standard or reduced intensity BEV for treatment of progressive GBM. Given the cost of BEV, these results have important implications for value in cancer care.

Clinical trial identification

Not applicable

Legal entity responsible for the study

Cancer Clinical Trials Unit (CCTU), Beaumont Hospital, Dublin, Ireland

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.